Please check your internet connection and try again.
# Tranexamic Acid
## Overview
Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots.
## Primary Indications
* **Trauma:** Management of hemorrhage in adult trauma patients at risk of significant bleeding.
* **Surgery:** Reduction of blood loss in orthopedic, cardiac, and spinal surgeries.
* **Obstetrics:** Management of primary postpartum hemorrhage (PPH).
* **Other:** Menorrhagia, epistaxis, and dental procedures in patients with bleeding disorders.
## Adult Dosing
* **Trauma (CRASH-2 protocol):** 1 g IV bolus over 10 minutes, followed by 1 g IV infusion over 8 hours.
* **Postpartum Hemorrhage:** 1 g IV over 10 minutes. A second 1 g dose may be administered if bleeding continues after 30 minutes.
* **Menorrhagia:** 1.3 g orally TID for up to 5 days during menstruation.
* **Surgery:** Highly protocol-dependent; ranges from 10–30 mg/kg IV bolus followed by variable infusion rates.
## Pediatric Dosing
* **Trauma:** 15 mg/kg (max 1 g) IV bolus, followed by 2 mg/kg/hour infusion for 8 hours (limited evidence, off-label).
* **General/Surgery:** 10–20 mg/kg IV; dosing varies significantly by institutional protocol.
## Dose Adjustments
* **Renal Impairment:** Required for moderate-to-severe impairment due to renal clearance of the drug. Administer lower doses or extend the dosing interval based on creatinine clearance (CrCl).
* CrCl 30–50 mL/min: Reduce dose by 50% or double the interval.
* CrCl <30 mL/min: Use with caution; monitor closely.
## Contraindications
* Active intravascular clotting (thromboembolic disease).
* History of venous or arterial thrombosis.
* Subarachnoid hemorrhage (potential for cerebral ischemia/vasospasm).
* Acquired defective color vision (cannot monitor for optic nerve toxicity).
* Hypersensitivity to tranexamic acid.
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal cramps (more common with oral dosing).
* **Neurological:** Seizures (notably with rapid IV administration or high doses), headache, dizziness.
* **Vascular:** Thromboembolic events (DVT, PE, MI, stroke).
* **Ocular:** Retinal venous/arterial occlusion, visual disturbances.
## Key Drug Interactions
* **Anticoagulants/Platelet Inhibitors:** Increased risk of bleeding if used concurrently; monitor for efficacy.
* **Factor IX complex/Prothrombin complex concentrates:** Increased risk of thrombosis if used concomitantly with antifibrinolytics.
* **Estrogens:** Increased risk of thrombosis when used with combined hormonal contraceptives.
## Monitoring
* **Clinical:** Monitor for signs of thromboembolism (e.g., limb swelling, chest pain, dyspnea).
* **Neurological:** Risk of seizure is increased, particularly during rapid IV push.
* **Ocular:** Baseline and periodic eye exams if long-term therapy is required.
* **Laboratory:** Renal function (CrCl) prior to and during therapy.
## Clinical Pearls
* **Timing is Key:** Benefit in trauma is time-dependent. Efficacy declines significantly if administered >3 hours post-injury.
* **Avoid IM:** Do not administer intramuscularly; this can cause tissue necrosis.
* **Avoid Intrathecal:** Accidental intrathecal administration is associated with high mortality and severe neurotoxicity; label syringes clearly to prevent medication errors.
* **IV Push:** Do not exceed 100 mg/minute for IV bolus to reduce the risk of hypotension and seizure.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Dosing protocols may vary significantly by institution and severity of clinical presentation. Always consult current local hospital guidelines and the manufacturer's prescribing information before administration.*
